Enliven Therapeutics (ELVN) investor relations material

Strategic focus and differentiation

• Developing a highly selective ATP-competitive BCR-ABL inhibitor for chronic myeloid leukemia, targeting patients with resistance to allosteric TKIs.

• Anticipates future unmet needs as resistance to allosteric inhibitors like SCEMBLIX increases.

• Emphasizes complementary mechanism to allosterics, aiming to address primary resistance.

• Considering combination studies with allosteric inhibitors to achieve treatment-free remission.

• Plans to initiate combination studies, pending collaboration and operational readiness.

Clinical data and competitive landscape

• Early data show 32% MMR in heavily pretreated, late-line patients, comparable to SCEMBLIX despite a more resistant population.

• Over half of evaluable patients had prior asciminib exposure, with 70% being refractory or resistant.

• TERN-701's high MMR rates are noted, but differences in patient selection and inclusion criteria complicate direct comparison.

• Response rates in multiply resistant patients are low, but higher in earlier lines of therapy.

• Ongoing studies will further clarify efficacy and safety, with updates expected next year.

Resistance, tolerability, and treatment dynamics

• Resistance mutations to allosteric inhibitors are increasing, driving the need for ATP-competitive options.

• Tolerability and quality of life are key, as minor adverse events can prompt treatment switches.

• Dose escalation with SCEMBLIX does not significantly improve molecular response rates.

• Real-world practice is evolving as new resistance mutations and treatment options emerge.

• NCCN guidelines are adapting to list mutations conferring resistance to allosterics, influencing treatment choices.